Literature DB >> 24719216

The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria: review of data from a referral centre.

Oliver Clifford-Mobley1, Christopher Tims2, Gill Rumsby2.   

Abstract

BACKGROUND: Urine oxalate measurement is an important investigation in the evaluation of renal stone disease. Primary hyperoxaluria (PH) is a rare inherited metabolic disease characterised by persistently elevated urine oxalate, but the diagnosis may be missed in adults until renal failure has developed. Urine oxalate results were reviewed to compare oxalate:creatinine ratio and oxalate excretion, and to estimate the potential numbers of undiagnosed PH.
METHODS: Urine oxalate results from August 2011 to April 2013 were reviewed. Oxalate excretion and oxalate:creatinine ratio were evaluated for 24 h collections and ratio alone for spot urine samples.
RESULTS: Oxalate:creatinine ratio and oxalate excretion were moderately correlated (R=0.63) in 24-h urine collections from patients aged 18 years and above. Sex-related differences were found requiring implementation of male and female reference ranges for oxalate:creatinine ratio. Of samples with both ratio and excretion above the reference range, 7% came from patients with confirmed PH. There were 24 patients with grossly elevated urine oxalate who had not been evaluated for PH.
CONCLUSIONS: Oxalate:creatinine ratio and oxalate excretion were discordant in many patients, which is likely to be a result of intra-individual variation in creatinine output and imprecision in the collection itself. Some PH patients had urine oxalate within the reference range on occasion, and therefore it is not possible to exclude PH on the finding of a single normal result. A significant number of individuals had urine oxalate results well above the reference range who potentially have undiagnosed PH and are consequently at risk of renal failure.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Clinical studies; Renal disease; inborn errors of metabolism

Mesh:

Substances:

Year:  2014        PMID: 24719216     DOI: 10.1177/0004563214529937

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  9 in total

1.  End Points for Clinical Trials in Primary Hyperoxaluria.

Authors:  Dawn S Milliner; Tracy L McGregor; Aliza Thompson; Bastian Dehmel; John Knight; Ralf Rosskamp; Melanie Blank; Sixun Yang; Sonia Fargue; Gill Rumsby; Jaap Groothoff; Meaghan Allain; Melissa West; Kim Hollander; W Todd Lowther; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-12       Impact factor: 8.237

2.  Urine oxalate biological variation in patients with primary hyperoxaluria.

Authors:  Oliver Clifford-Mobley; Anna Sjögren; Elisabeth Lindner; Gill Rumsby
Journal:  Urolithiasis       Date:  2016-02-08       Impact factor: 3.436

3.  Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.

Authors:  Wesley Hayes; David J Sas; Daniella Magen; Hadas Shasha-Lavsky; Mini Michael; Anne-Laure Sellier-Leclerc; Julien Hogan; Taylor Ngo; Marianne T Sweetser; John M Gansner; Tracy L McGregor; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2022-08-01       Impact factor: 3.651

4.  Absence of the sulfate transporter SAT-1 has no impact on oxalate handling by mouse intestine and does not cause hyperoxaluria or hyperoxalemia.

Authors:  Jonathan M Whittamore; Christine E Stephens; Marguerite Hatch
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-01       Impact factor: 4.052

5.  Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria.

Authors:  Oliver Clifford-Mobley; Gill Rumsby; Swati Kanodia; Mohammed Didi; Richard Holt; Senthil Senniappan
Journal:  Pediatr Nephrol       Date:  2017-07-27       Impact factor: 3.714

6.  Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing.

Authors:  Emma L Williams; Eleanor A L Bagg; Michael Mueller; Jana Vandrovcova; Timothy J Aitman; Gill Rumsby
Journal:  Mol Genet Genomic Med       Date:  2015-01       Impact factor: 2.183

7.  Epidemiology of paediatric renal stone disease: a 22-year single centre experience in the UK.

Authors:  Naomi Issler; Stephanie Dufek; Robert Kleta; Detlef Bockenhauer; Naima Smeulders; William Van't Hoff
Journal:  BMC Nephrol       Date:  2017-04-18       Impact factor: 2.388

8.  Relationship of spot urine oxalate to creatinine ratio and 24 hours urinary oxalate excretion in patients with urolithiasis.

Authors:  Syed Bilal Hashmi; Lena Jafri; Hafsa Majid; Jamsheer Talati; Wajahat Aziz; Aysha Habib Khan
Journal:  Ann Med Surg (Lond)       Date:  2020-11-07

9.  Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1.

Authors:  Benedetta Chiodini; Nathalie Tram; Brigitte Adams; Elise Hennaut; Ksenija Lolin; Khalid Ismaili
Journal:  Front Pediatr       Date:  2022-01-05       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.